Company research
Apyx Medical Corp
CIK 719135Updated Nov 20, 2026
APYX price & chart
Loading TradingView…
NASDAQ:APYX on TradingView ↗In the news
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results ↗
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 ↗
Seeking Alpha
Apyx Medical Corporation (APYX) Presents at 2026 UBS Global Healthcare Conference Transcript ↗
Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript ↗
InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair ↗
SEC disclosures
Apyx Medical Corp files 8-K: Material Event ↗
Recent filings
S-8 filing
10-Q filing
8-K filing
Other Events
Items 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 57,365,000Source | 60,721,000Source | 61,072,000Source | 58,188,000Source | 65,394,000Source | 63,025,000Source | 60,160,000Source | 70,711,000Source | 66,840,000Source | 64,842,000Source | 79,240,000Source | 51,775,000Source |
| Property, Plant and Equipment, NetUSD | 2,390,000Source | 1,905,000Source | 2,110,000Source | 2,048,000Source | 1,918,000Source | 2,235,000Source | 1,910,000Source | 1,779,000Source | 2,371,000Source | 1,987,000Source | 1,915,000Source | 6,761,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 25,135,000Source | 28,013,000Source | 27,617,000Source | 29,301,000Source | 32,678,000Source | 31,137,000Source | 31,011,000Source | 37,282,000Source | 31,740,000Source | 31,741,000Source | 43,652,000Source | 10,192,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 12,995,000Source | 13,036,000Source | 13,614,000Source | 11,248,000Source | 12,709,000Source | 12,755,000Source | 11,645,000Source | 12,487,000Source | 16,776,000Source | 15,480,000Source | 14,023,000Source | 10,602,000Source |
| Inventory, NetUSD | 9,145,000Source | 9,000,000Source | 10,747,000Source | 8,192,000Source | 9,324,000Source | 9,536,000Source | 7,685,000Source | 9,795,000Source | 8,602,000Source | 7,564,000Source | 9,923,000Source | 11,797,000Source |
| Assets, CurrentUSD | 48,788,000Source | 52,158,000Source | 53,155,000Source | 49,915,000Source | 56,671,000Source | 54,795,000Source | 51,851,000Source | 61,926,000Source | 58,471,000Source | 56,440,000Source | 70,362,000Source | 42,972,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,513,000Source | 2,109,000Source | 1,177,000Source | 1,174,000Source | 1,960,000Source | 1,367,000Source | 1,510,000Source | 2,362,000Source | 1,353,000Source | 1,655,000Source | 2,734,000Source | 2,737,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,342,000Source | 4,820,000Source | 4,014,000Source | 4,464,000Source | 4,935,000Source | 4,092,000Source | 4,584,000Source | 5,049,000Source | 4,218,000Source | 4,703,000Source | 5,162,000Source | 710,000Source |
| Other Assets, NoncurrentUSD | 1,812,000Source | 1,785,000Source | 1,776,000Source | 1,723,000Source | 1,811,000Source | 1,881,000Source | 1,772,000Source | 1,893,000Source | 1,752,000Source | 1,664,000Source | 1,732,000Source | 1,217,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 51,285,000Source | 49,524,000Source | 49,982,000Source | 50,732,000Source | 50,470,000Source | 49,937,000Source | 49,516,000Source | 50,251,000Source | 52,009,000Source | 50,507,000Source | 52,318,000Source | 13,982,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 38,000Source | 35,000Source | 42,000Source | 38,000Source | 35,000Source | 42,000Source | 38,000Source | 35,000Source | 42,000Source | 38,000Source | 35,000Source | 35,000Source |
| Additional Paid in CapitalUSD | 93,633,000Source | 84,289,000Source | 105,094,000Source | 93,054,000Source | 83,292,000Source | 104,020,000Source | 92,534,000Source | 82,242,000Source | 103,620,000Source | 92,083,000Source | 81,114,000Source | 73,282,000Source |
| Retained Earnings (Accumulated Deficit)USD | -87,823,000Source | -73,283,000Source | -94,473,000Source | -85,839,000Source | -68,580,000Source | -91,230,000Source | -82,061,000Source | -62,024,000Source | -89,122,000Source | -77,911,000Source | -54,448,000Source | -35,735,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,848,000Source | 11,041,000Source | 10,663,000Source | 7,253,000Source | 14,747,000Source | 12,832,000Source | 10,511,000Source | 20,253,000Source | 14,540,000Source | 14,210,000Source | 26,701,000Source | 37,582,000Source |
| Liabilities and EquityUSD | 57,365,000Source | 60,721,000Source | 61,072,000Source | 58,188,000Source | 65,394,000Source | 63,025,000Source | 60,160,000Source | 70,711,000Source | 66,840,000Source | 64,842,000Source | 79,240,000Source | 51,775,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,978,000Source | 9,555,000Source | 9,354,000Source | 10,566,000Source | 10,639,000Source | 9,447,000Source | 9,510,000Source | 10,556,000Source | 11,700,000Source | 10,721,000Source | 12,740,000Source | 11,850,000Source |
| Operating Lease, Liability, CurrentUSD | 393,000Source | 330,000Source | 451,000Source | 378,000Source | 313,000Source | 420,000Source | 354,000Source | 356,000Source | 407,000Source | 335,000Source | 347,000Source | 216,000Source |
| Accounts Payable, CurrentUSD | 3,220,000Source | 1,914,000Source | 2,190,000Source | 2,893,000Source | 2,348,000Source | 2,629,000Source | 2,305,000Source | 2,103,000Source | 3,058,000Source | 2,615,000Source | 2,712,000Source | 2,669,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,173,000Source | 4,606,000Source | 3,828,000Source | 4,292,000Source | 4,697,000Source | 3,926,000Source | 4,387,000Source | 4,795,000Source | 4,051,000Source | 4,483,000Source | 4,896,000Source | 470,000Source |
| Other Liabilities, NoncurrentUSD | 293,000Source | 201,000Source | 336,000Source | 292,000Source | 192,000Source | 339,000Source | 270,000Source | 194,000Source | 347,000Source | 259,000Source | 198,000Source | 181,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 232,000Source | 156,000Source | 427,000Source | 203,000Source | 177,000Source | 256,000Source | 133,000Source | 207,000Source | 291,000Source | 125,000Source | 221,000Source | 211,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,344,000Source | 7,291,000Source | 6,692,000Source | 7,275,000Source | — | 6,377,000Source | 6,831,000Source | — | 8,214,000Source | 7,751,000Source | — | 8,928,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,307,000Source | 1,359,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 34,607,000Source | 33,853,000Source | 35,328,000Source | 34,365,000Source | 33,628,000Source | 35,087,000Source | 34,127,000Source | 33,406,000Source | 34,849,000Source | 33,893,000Source | 33,185,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -1,955,000Source | -4,724,000Source | -3,072,000Source | -3,738,000Source | -2,143,000Source | -4,172,000Source | -11,105,000Source | -23,559,000Source | -18,850,000Source | -23,278,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 202,000Source | 138,000Source | 655,000Source | 599,000Source | 692,000Source | 890,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 312,000Source | 451,000Source | 2,001,000Source | 4,013,000Source | 5,114,000Source | 6,697,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -3,952,000Source | -3,942,000Source | 1,318,000Source | 2,035,000Source | 3,574,000Source | -1,918,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 845,000Source | 199,000Source | 1,074,000Source | -2,263,000Source | -1,459,000Source | 5,568,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -411,000Source | -331,000Source | 355,000Source | -63,000Source | 25,000Source | 67,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | -4,254,000Source | -4,375,000Source | -5,100,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -572,000Source | -702,000Source | -8,001,000Source | -18,047,000Source | -5,249,000Source | -20,280,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -60,000Source | -55,000Source | -1,114,000Source | -722,000Source | 6,734,000Source | -1,010,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 60,000Source | 55,000Source | 1,114,000Source | 722,000Source | 533,000Source | 1,010,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 83,000Source | 25,000Source | 9,580,000Source | 6,745,000Source | 32,166,000Source | 217,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -603,000Source | -730,000Source | -1,000Source | -11,911,000Source | 33,460,000Source | -20,678,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | — | 43,652,000Source | 10,192,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,131,000Source | 1,145,000Source | 4,636,000Source | 4,746,000Source | 1,935,000Source | 15,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 1,000Source | 258,000Source | 382,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | 113,000Source | -191,000Source | 395,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 530,000Source | 997,000Source | 1,074,000Source | 520,000Source | 312,000Source | 451,000Source | 2,001,000Source | 4,013,000Source | 5,114,000Source | 6,697,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 700,000Source | 600,000Source | 700,000Source | 700,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | — | -75,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | 0Source | -19,000Source | -13,000Source | 2,531,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | -3,088,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 78,000Source | 60,000Source | 124,000Source | 49,000Source | 143,000Source | 49,000Source | 270,000Source | 252,000Source | -2,432,000Source | 367,000Source |
| InterestExpenseNonoperatingUSD | — | — | 1,413,000Source | 1,431,000Source | 1,394,000Source | 1,393,000Source | 1,369,000Source | 1,376,000Source | 5,589,000Source | 5,907,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 10,000Source | 28,000Source | 341,000Source | 163,000Source | — | — |
| Investment Income, InterestUSD | — | — | 292,000Source | 378,000Source | 250,000Source | 278,000Source | 244,000Source | 304,000Source | 1,108,000Source | 1,606,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,984,000Source | -4,703,000Source | -3,243,000Source | -3,778,000Source | -2,108,000Source | -4,150,000Source | -11,211,000Source | -23,463,000Source | -18,713,000Source | -23,184,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 29,000Source | -21,000Source | 171,000Source | 40,000Source | -35,000Source | -22,000Source | 106,000Source | -96,000Source | -137,000Source | -94,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -1,984,000Source | -4,703,000Source | -3,243,000Source | -3,778,000Source | -2,108,000Source | -4,150,000Source | -11,211,000Source | -23,463,000Source | -18,713,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -1,045,000Source | -1,029,000Source | -1,142,000Source | -1,115,000Source | -1,089,000Source | -1,072,000Source | -4,389,000Source | -4,462,000Source | — | — |
| Operating ExpensesUSD | — | — | 9,129,000Source | 10,589,000Source | 10,676,000Source | 9,657,000Source | 8,836,000Source | 8,716,000Source | 39,490,000Source | 48,205,000Source | 53,710,000Source | 52,693,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 24,000Source | — | 0Source | — | 0Source | — | -161,000Source | -4,023,000Source | 651,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 76,000Source | 24,000Source | 2,000Source | 0Source | 36,000Source | 0Source | 92,000Source | -161,000Source | 622,000Source | 509,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 43,474,000Source | — |
| Proceeds from Noncontrolling InterestsUSD | — | — | — | — | — | — | 0Source | 30,000Source | 60,000Source | 0Source | 147,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 88,000Source | 0Source | 488,000Source | 0Source | 86,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 12,877,000Source | 11,487,000Source | 13,884,000Source | 11,373,000Source | 12,490,000Source | 9,430,000Source | 52,844,000Source | 48,102,000Source | — | — |
| Amortization of Debt Issuance Costs | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 12,877,000Source | 11,487,000Source | 13,884,000Source | 11,373,000Source | 12,490,000Source | 9,430,000Source | 52,844,000Source | 48,102,000Source | 52,349,000Source | 44,510,000Source |
| Cost of RevenueUSD | — | — | 4,580,000Source | 4,533,000Source | 5,014,000Source | 4,290,000Source | 4,565,000Source | 3,765,000Source | 19,800,000Source | 18,742,000Source | 18,590,000Source | 15,379,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 3,656,000Source | 4,291,000Source | 5,285,000Source | 4,265,000Source | 3,576,000Source | 3,466,000Source | 15,803,000Source | 18,858,000Source | 22,198,000Source | 20,484,000Source |
| Operating Income (Loss)USD | — | — | -832,000Source | -3,635,000Source | -1,806,000Source | -2,574,000Source | -911,000Source | -3,051,000Source | -6,446,000Source | -18,845,000Source | -17,259,000Source | -23,562,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 24,000Source | — | 0Source | — | 0Source | — | -161,000Source | -4,023,000Source | 651,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -1,877,000Source | -4,664,000Source | -2,948,000Source | -3,689,000Source | -2,000,000Source | -4,123,000Source | -10,835,000Source | -23,307,000Source | -21,282,000Source | -22,911,000Source |
| Income Tax Expense (Benefit)USD | — | — | 78,000Source | 60,000Source | 124,000Source | 49,000Source | 143,000Source | 49,000Source | 270,000Source | 252,000Source | -2,432,000Source | 367,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 29,000Source | -21,000Source | 171,000Source | 40,000Source | -35,000Source | -22,000Source | 106,000Source | -96,000Source | -137,000Source | -94,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,984,000Source | -4,703,000Source | -3,243,000Source | -3,778,000Source | -2,108,000Source | -4,150,000Source | -11,211,000Source | -23,463,000Source | -18,713,000Source | -23,184,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.05Source | -0.14Source | -0.07Source | -0.09Source | -0.05Source | -0.1Source | -0.27Source | -0.66Source | -0.54Source | -0.67Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | — | — | — | — | — | -0.54Source | -0.67Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 40,748,000Source | 34,644,000Source | 43,850,000Source | 40,729,000Source | 43,742,000Source | 40,729,000Source | 41,095,000Source | 35,542,000Source | 34,622,000Source | 34,516,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | — | — | 34,622,000Source | 34,516,000Source |
| Interest Expense (non-operating)USD | — | — | 1,413,000Source | 1,431,000Source | 1,394,000Source | 1,393,000Source | 1,369,000Source | 1,376,000Source | 5,589,000Source | 5,907,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 270,000Source | 252,000Source | -2,432,000Source | 367,000Source |
| Gross ProfitUSD | — | — | 8,297,000Source | 6,954,000Source | 8,870,000Source | 7,083,000Source | 7,925,000Source | 5,665,000Source | 33,044,000Source | 29,360,000Source | 33,759,000Source | 29,131,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -13,855,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,478,000Source | 15,000Source |
| Interest Income, OperatingUSD | — | — | — | — | — | — | — | — | — | — | 921,000Source | 157,000Source |
| Investment Income, InterestUSD | — | — | 292,000Source | 378,000Source | 250,000Source | 278,000Source | 244,000Source | 304,000Source | 1,108,000Source | 1,606,000Source | — | — |
| Labor and Related ExpenseUSD | — | — | 3,191,000Source | 3,508,000Source | 3,374,000Source | 3,072,000Source | 3,253,000Source | 3,081,000Source | 14,011,000Source | 17,353,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -1,984,000Source | -4,703,000Source | -3,243,000Source | -3,778,000Source | -2,108,000Source | -4,150,000Source | -11,211,000Source | -23,463,000Source | -18,713,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -1,045,000Source | -1,029,000Source | -1,142,000Source | -1,115,000Source | -1,089,000Source | -1,072,000Source | -4,389,000Source | -4,462,000Source | — | — |
| Operating ExpensesUSD | — | — | 9,129,000Source | 10,589,000Source | 10,676,000Source | 9,657,000Source | 8,836,000Source | 8,716,000Source | 39,490,000Source | 48,205,000Source | 53,710,000Source | 52,693,000Source |
| Other ExpensesUSD | — | — | 7,874,000Source | 9,457,000Source | 9,529,000Source | 8,705,000Source | 7,770,000Source | 7,877,000Source | 34,428,000Source | 43,659,000Source | — | — |
| Other Operating Income (Expense), NetUSD | — | — | 76,000Source | 24,000Source | 2,000Source | 0Source | 36,000Source | 0Source | 92,000Source | -161,000Source | 622,000Source | 509,000Source |
| Research and Development ExpenseUSD | — | — | 801,000Source | 1,142,000Source | 793,000Source | 824,000Source | 765,000Source | 804,000Source | 3,373,000Source | 5,080,000Source | 4,844,000Source | 4,544,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 12,877,000Source | 11,487,000Source | 13,884,000Source | 11,373,000Source | 12,490,000Source | 9,430,000Source | 52,844,000Source | 48,102,000Source | — | — |
Filing attachments
ex107.htm · S-8 · 2026-11-19
Calculation of Filing Fee Tables S-8 Apyx Medical Corp ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ─────────────────────────────────────────────────…
Read attachment ↗ex99-2.htm · S-8 · 2026-11-19
Exhibit 99.2 STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (the “ Agreement ”) is effective as of August 4, 2025 (the “ Grant Date ”), by and between Apyx Medical Corporation, a Delaware corporation (the “ Corporation ”) and John Featherstone (the “ Optionee ”). WHEREAS, as an inducement to Optionee to be employed by the Corporation, the Corporation hereby grants Optionee the right and option to purchase up to 100,000 shares of common stock of the Corporation, par value $0.001 per share …
Read attachment ↗ex99-1.htm · 8-K · 2025-11-19
EX-99.1 4 ex99-1.htm EX-99.1 Exhibit 99.1 Apyx Medical Corporation Announces Proposed Public Offering of Common Stock CLEARWATER FL, November 17, 2025 - Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to…
Read attachment ↗ex99-2.htm · 8-K · 2025-11-19
EX-99.2 5 ex99-2.htm EX-99.2 Exhibit 99.2 Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock CLEARWATER FL, November 18, 2025 - Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offeri…
Read attachment ↗